Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DNM2 | P50570 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9649828 | 0.83 | TAAR1 (0.36) | UTS2RTAAR1MAPTKCNH2DNM2 | |
| SCHEMBL11318303 | 0.81 | TDP1 (0.49) | TAAR1MAPTLMNANPSR1TDP1 | |
| SCHEMBL14229179 | 0.79 | UTS2R (0.39) | UTS2RCRHR1MAPTLMNAMAPK1 | |
| SCHEMBL16548435 | 0.77 | LMNA (0.40) | UTS2RCRHR1MAPTLMNAMAPK1 | |
| SCHEMBL14229041 | 0.77 | UTS2R (0.38) | UTS2RCRHR1MAPTLMNAMAPK1 | |
| SCHEMBL22576537 | 0.76 | TAAR1 (0.38) | TAAR1KCNH2 | |
| SCHEMBL20197196 | 0.76 | UTS2R (0.38) | UTS2RCRHR1MAPTLMNAMAPK1 | |
| SCHEMBL14200180 | 0.76 | UTS2R (0.38) | UTS2RCRHR1MAPTLMNAMAPK1 | |
| SCHEMBL27528977 | 0.75 | SMN1; SMN2 (0.40) | UTS2RCRHR1MAPTLMNANPSR1 | |
| SCHEMBL893473 | 0.75 | SMN1; SMN2 (0.45) | UTS2RCRHR1MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| EP-0885215-B1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1609790-A2 | Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | Abbott Laboratories (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| CN-1384100-A | Benzo-1,3-dioxole and benzofuran substituted pentazane derivative | ABBOTT CO (US) | 2002-12-11 | — | — | CN | disclosed |
| US-6462194-B1 | Endothelin antagonists | ABBOTT LABORATORIES | 2002-10-08 | — | — | US | disclosed |
| CN-1091768-C | Novel benzo-1, 3-dioxolyl-and benzofuranyl-substituted pyrrolidine derivatives as endothelin antagonists | ABBOTT LAB CO (US) | 2002-10-02 | — | — | CN | disclosed |
| EP-0776324-B1 | ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6380241-B1 | FOR THERAPY OF CORONARY ANGINA, CEREBRAL VASOSPASM, ACUTE AND CHRONIC RENAL FAILURE, GASTRIC ULCERATION, CYCLOSPORIN-INDUCED NEPHROTOXICITY, ENDOTOXIN-INDUCED TOXICITY, ASTHMA, LPL-RELATED LIPOPROTEIN DISORDERS, PROLIFERATIVE DISEASES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| EP-1186603-A2 | Processes for preparing endothelin antagonists | Abbott Laboratories (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
| CN-1219172-A | Novel benzo-1, 3-dioxolyl-and benzofuranyl-substituted pyrrolidine derivatives as endothelin antagonists | ABBOTT LAB CO (US) | 1999-06-09 | — | — | CN | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5767144-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 1998-06-16 | — | — | US | disclosed |
| US-5731434-A | CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5622971-A | PIPERIDINE DERIVATIVES; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | UTS2R 339/4885TAAR1 357/4885CRHR1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.